All In Biotech

NDA 211321 · Ucb INC

Nayzilam

Midazolam · Nasal · Benzodiazepine

Orphan

Last checked: Nov 20, 2026Latest source record: Jan 13, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

May 17, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,448

153 Phase 3, 96 recruiting

FAERS reports

25,623

23,715 serious, 4,786 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death . Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [see Warnings and Precautions (5.1) and Drug Interactions (7.2) ] . The use of benzodiazepines, including NAYZILAM, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse...

What it is approved for

From the label in effect Oct 16, 2026.

NAYZILAM is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older. NAYZILAM is a benzodiazepine indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older. ( 1 )

Mechanism: The exact mechanism of action for midazolam is not fully understood, but it is thought to involve potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABA A receptor.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • NAYZILAM · MIDAZOLAM 5MG/SPRAY · SPRAY, NASAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Midazolam" as an intervention, any sponsor and status, largest first.

All 1,448 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective3,208
  • off label use2,487
  • seizure1,639
  • hypotension1,399
  • drug interaction1,152
  • acute kidney injury895
  • toxicity to various agents881
  • pyrexia858
  • cardiac arrest853
  • death720
  • status epilepticus670
  • condition aggravated655

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200458
2005155
2006119
200725
200832
200942
2010110
2011321
2012723
2013724
2014814
20151,068
20161,173
20171,339
20181,686
20191,933
20202,254
20212,623
20221,999
20232,356
20242,168
20252,361
20261,540

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nayzilam (Midazolam)

2024 spending

$36.9M

Beneficiaries

18,184

39,175 claims

Per beneficiary

$2,027

$327.23 per unit

View as table
YearSpending
2020$6,483,915
2021$11,990,591
2022$18,754,348
2023$27,518,709
2024$36,864,379

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,612 on PubMed

Sponsor: UCB

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.